



SINO SECURITIES INTERNATIONAL LIMITED



Address: 3rd Floor, 43-51 Queen Street
Melbourne, VIC 3000, Australia

ABN 99 006 620 739

Sino Investment Services Pty Ltd (ABN 49 006 643 152)

Sino GL Pty Ltd (ABN 29 090 447 368)

SSI Nominees Pty Ltd (ABN 31 006 724 956)

Sino Investments Pty Ltd (ABN 47 006 643 143)

Sino Asset Management Pty Ltd (ABN 61 007 282 797)

Sino Finance Portal Pty Ltd (ABN 32 086 928 396)

Telephone: (61) 3 9629 6615

Facsimile: (61) 3 9614 1946

E-Mail: info@sino.com.au

Web Site: <http://www.sino.com.au> <http://www.myprofit.com.au>

19 August 2005

Company Announcement Office
Australian Stock Exchange Limited

Dear Sir/Madam

**Re: TGA approves Pharmasafe's Liver Bioguard as listed product
Pharmasafe enters into Distribution Agreement with GoConnect for Liver
Bioguard**

Sino Securities International Ltd ("SSI") and Pharmasafe Pty Ltd ("Pharmasafe") are pleased to advise that Pharmasafe's Chinese herbal remedy, Liver Bioguard, has received final approval from the Australian Therapeutic Goods Administration for sale as a listed product. Professor TC Lin and SSI joined forces in January 2002 to establish Pharmasafe to promote and distribute complementary Chinese medicine. Liver Bioguard is the first complementary Chinese medicine product owned and to be distributed by Pharmasafe. SSI holds 40% of Pharmasafe.

GoConnect Ltd ("GCN") is also pleased to advise that its wholly owned subsidiary, GoConnect Australia Pty Ltd ("GAP") has entered into an agreement with Pharmasafe Pty Ltd ("Pharmasafe") for GAP to develop the Pharmasafe Internet site located at www.pharmasafe.com.au and to act as exclusive Internet distribution agent for Pharmasafe products in return for a revenue share on sales. The first product that will be distributed via the Pharmasafe website will be Liver Bioguard, a Chinese herbal remedy developed by Professor Lin from over 20 years of research and practical application. Liver Bioguard helps to restore the human liver, affected by viral infections, to normal conditions.

The liver is the largest gland in the body. The liver filters blood from both the portal and systemic circulations. The body depends on the liver to regulate, synthesize, store, and secrete many important proteins and nutrients and to purify, transform, and clear toxic or unneeded substances. Normal liver functions can be affected by a number of diseases. Most commonly, the liver can be impaired by Hepatitis related to viral infections or medications and cirrhosis related to alcoholism. Hepatitis B Virus ("HBV") Infection is the most common form of viral infection of the liver: HBV is 100 times more infectious than HIV, the virus that can cause AIDS. An estimated 350 million people are infected globally with HBV. Approximately 1 million die each year from complications from HBV. The next most common form of liver viral infection is Hepatitis C Virus ("HCV") Infection which cannot be vaccinated against. 3% of the world's population is infected with HCV, or approximately 170 million.

© COPYRIGHT RESERVED

For personal use of clients of the Sino Securities International Ltd group. The advice and information is believed accurate and reliable but no such warranty is given and no responsibility is accepted by the company or any member or employee for any loss or damage whatsoever arising in any way for any representation, act or omission, whether expressed or implied (including responsibility to any person by reason of negligence). The Sino group may be beneficial owners or have a financial interest in the investments or transactions discussed.

Pharmasafe's Liver Bioguard works to restore the viral infected liver to normal functions by restoring the body's natural immunity to a state that enables the body to combat liver viral infections and improves well-being to the body. Liver Bioguard can be ordered directly from www.pharmasafe.com.au.

Yours sincerely

Richard Li
Managing Director
Sino Securities International Ltd